Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Lab tests aim to tailor cancer treatments for patients who've run out of options

NCT ID NCT06024603

Knowledge-focused Sponsor: Case Comprehensive Cancer Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 07, 2026 · Updated 2 times

Summary

This study tests whether doctors can quickly recommend personalized cancer treatments for adults whose cancers have returned or stopped responding to standard therapy. Researchers will take a sample of the tumor, test it against many drugs in the lab, and also analyze its genes. The goal is to see if they can provide a ranked list of treatment options within 4 weeks for at least 22 out of 36 participants. This approach could help match patients to drugs that might work better for their specific cancer.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Drug Sensitivity Test (DST) and genomic profiling
What this could lead to
If successful, this could pave the way for personalized cancer treatments tailored to each patient's tumor, potentially improving outcomes for those with limited options.
What could go wrong
This is a small, early feasibility study (36 participants) focused on whether recommendations can be made in time, not on effectiveness. The approach may not work for all cancer types or may not improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

36 people

The number who actually took part.

Started

Nov 2023

Finished

Dec 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants aged 18 years or older at the time of enrollment on this study of any gender, race, or ethnicity. * Patients with suspected or confirmed diagnosis of recurrent or refractory cancer with no curative treatment options. * Participants who have undergone at least two lines of previous therapy. * Participants who are scheduled for or have recently had biopsy or tumor excised (solid tumors) or bone marrow aspirate (blood cancers) or who have scheduled or recently had paracentesis or thoracentesis performed. * Participants willing to have a blood draw or buccal swab done for the purposes of genetic testing. * Participants willing to sign informed consent. Exclusion Criteria: * Participants who do not have malignant tissue available and accessible. * Participants for whom the amount of excised malignant tissue is not sufficient for the ex vivo drug testing and/or genetic profiling. * Participants with newly diagnosed tumors and tumors that have high (\>90%) cure rate with safe standard therapy.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Refractory cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

neoplasm Recurrence refractory malignant neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Refractory cancer Relapsed cancer

Contacts and locations

Locations

  • Florida International University

    Miami, Florida, 33199, United States

  • Lerner College of Medicine, Cleveland Clinic Florida

    Weston, Florida, 33331, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.